Frontlight ResearchEarly access
Childhood cancers trials in Israel
35 of 43 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Ramat Gan, Tel Aviv
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 1/2Taking peopleSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Where
- Ramat Gan
- Age
- 1 year to 30 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07387926 - Phase 2/3Taking peopleA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Age
- 12 years and over
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00 - Phase 1/2Taking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - Phase 2/3Taking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Beersheba, Jerusalem, Tel Aviv, Tel-Hashomer
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Haifa, Ramat Gan
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1/2Taking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Haifa, Petah Tikva, Ramat Gan
- Age
- 1 month to 17 years
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - Phase 3Not yet taking people in IsraelInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Tel Aviv
- Age
- 1 year to 64 years
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - Phase 3Taking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Petah Tikva
- Age
- 1 day to 1 year
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - Phase 1/2Taking peopleA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Where
- Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan
- Age
- 30 days and over
- People
- 447 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Beersheba, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 1/2Taking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Haifa, Ramat Gan
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - Phase 1/2Taking peopleA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
- Where
- Jerusalem, Tel Aviv
- People
- 64 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07602777 - Phase 2Taking peopleA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Where
- Haifa, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00 - Phase 2Taking peoplePatients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
- Where
- Jerusalem
- Age
- 12 months to 21 years
- People
- 10
- Run by
- Shaare Zedek Medical Center
See details and how to joinNCT07537400 - Phase 2/3Active, not recruitingAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- Where
- Haifa, Petah Tikva, Tel Aviv
- Age
- 1 month to 18 years
- People
- 1,800 worldwide
- Run by
- St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Where
- Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 12 years and over
- People
- 100 worldwide
- Run by
- AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00 - Phase 2Taking peopleCombination Therapy for the Treatment of Diffuse Midline Gliomas
- Where
- Jerusalem, Tel HaShomer
- Age
- 2 years to 39 years
- People
- 360 worldwide
- Run by
- University of California, San Francisco
See details and how to joinNCT05009992 · EU 2023-507598-16-00 - Phase 3Not yet taking people in IsraelInternational Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- Up to 18 years
- People
- 683 worldwide
- Run by
- University Hospital Muenster
See details and how to joinNCT04043494 · EU 2023-508101-24-00 - Phase 3Taking peopleONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Petah Tikvah, Ramat Gan, Tel Aviv
- People
- 510 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05580562 · EU 2022-502051-56-00 - Phase 1/2Not yet taking people in IsraelA Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
- Where
- Ramat Gan
- Age
- 1 year to 80 years
- People
- 50
- Run by
- Sheba Medical Center
See details and how to joinNCT07503353 - Phase 2Taking peopleInternational Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Where
- Tel Aviv
- Age
- Up to 17 years
- People
- 250 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT03590171 · EU 2024-513070-21-00 - Phase 1/2Taking peopleA Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
- Where
- Ramat Gan
- Age
- 1 year to 80 years
- People
- 50
- Run by
- Sheba Medical Center
See details and how to joinNCT07135466 - Phase 1/2Taking peopleModified Vaccine for High Risk or Low Residual Melanoma Patients
- Where
- Jerusalem
- People
- 50
- Run by
- Hadassah Medical Organization
See details and how to joinNCT01898039